Patients’ Perspectives on Alternative Antibiotic Treatment Strategies for Infective Endocarditis Among Persons Who Inject Drugs
Authors:
- D. Kane CooperDCD. Kane Cooper
- Eunice A. OkumuEOEunice A. Okumu
- Bailey McInnesBMBailey McInnes
- Maisun M. AnsaryMAMaisun M. Ansary
- Maria EspositoMEMaria Esposito
- Carson MerenbloomCMCarson Merenbloom
- Bayla OstrachBOBayla Ostrach
- Vivian H. ChuVCVivian H. Chu
- Li-Tzy WuLWLi-Tzy Wu
- Carol GolinCGCarol Golin
- David L. RosenDRDavid L. Rosen
- Asher J. SchranzASAsher J. Schranz
- 17 July 2025
- journal article
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 20 (3) , 328-334
Abstract
Objectives: Injection drug use is a leading and growing risk factor for infective endocarditis (IE), as evidenced by a marked national increase in hospitalizations for drug use–associated infective endocarditis (DUA-IE). The typical treatment approach for persons with DUA-IE is a 6-week inpatient course of intravenous antimicrobials. This approach is resource-intensive, requiring substantial hospital resources and lengthy stays. Alternative methods of antibiotic delivery for DUA-IE treatment have been proposed and piloted, but their acceptance among people who inject drugs is unknown. Methods: Persons hospitalized with DUA-IE (N = 16) completed semi-structured interviews to identify facilitators and barriers to 3 proposed IE treatment options: (A) hospitalization for the entirety of antibiotic treatment, the current standard of care; (B) home-based outpatient parenteral antimicrobial therapy via indwelling catheter; or (C) weekly outpatient visits for long-acting antibiotic infusion. Interviews were transcribed and thematically coded to identify participant perspectives and preferences among these strategies. Results: Option A was ranked the most preferred treatment regimen (8 participants, 50%), followed by options C (5 participants, 31%) and B (3 participants, 19%). Participants felt option A provided the most effective treatment for their endocarditis, despite dissatisfaction with the hospitalization length. Options B and C appealed to participants given the convenience of outpatient care; however, inadequate transportation and housing instability were prominently cited as barriers. Conclusions: These diverse patient perspectives should inform trials to evaluate the effectiveness of alternative antibiotic delivery strategies, as well as interventions to improve patient-centered decision-making for DUA-IE treatment.Keywords
This publication has 23 references indexed in Scilit:
- Estimated Number of People Who Inject Drugs in the United StatesClinical Infectious Diseases, 2022
- Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapyAntimicrobial Stewardship & Healthcare Epidemiology, 2022
- Diagnosis and Management of Infective Endocarditis in People Who Inject DrugsJACC, 2022
- Can I Safely Discharge a Patient with a Substance Use Disorder Home with a Peripherally Inserted Central Catheter?NEJM Evidence, 2022
- Infective endocarditis in intravenous drug usersTrends in Cardiovascular Medicine, 2020
- Dalbavancin for infective endocarditis: a single centre experienceJournal of Chemotherapy, 2020
- The Evolving Burden of Drug Use Associated Infective Endocarditis in the United StatesThe Annals of Thoracic Surgery, 2020
- Clinical Outcomes of Infective Endocarditis in Injection Drug UsersJACC, 2019
- In-hospital illicit drug use, substance use disorders, and acceptance of residential treatment in a prospective pilot needs assessment of hospitalized adults with severe infections from injecting drugsJournal of Substance Abuse Treatment, 2018
- A 9-Point Risk Assessment for Patients Who Inject Drugs and Require Intravenous Antibiotics: Focusing Inpatient Resources on Patients at Greatest Risk of Ongoing Drug UseClinical Infectious Diseases, 2018